Compare Agilent Technologies Inc (A) vs RLX Technology Inc (RLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs RLX Technology Inc — how do they compare? Agilent Technologies Inc trades at $128.68 (market cap $37.04B), while RLX Technology Inc trades at $1.98 (market cap $2.32B). The key difference: Agilent Technologies Inc is far larger — about 16× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.26%). Which is the better fit depends on your goals.
| A | RLX | |
|---|---|---|
Market Cap | $37.04B | $2.32B |
Sector | Health | Technology |
52-Week High | $157.20 | $2.73 |
52-Week Low | $110.24 | $1.79 |
Enterprise Value | $38.59B | $955.96M |
Dividend Yield | 0.78% | 5.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
RLX stock trades at $1.96, up 1.55% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported strong 2025 results with $3.62B revenue and $922M net income, though recent quarters have missed EPS expectations. Positive news highlights international expansion and a cash-rich, debt-free balance sheet, with JPMorgan increasing its stake significantly in Q3 2025.
Outlook is cautiously optimistic given solid profitability and industry growth potential, but risks include regulatory scrutiny in the vaping sector and consistent earnings misses. The sole analyst coverage recommends Hold, reflecting balanced risk-reward amid high cash flows but uncertain near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
